Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease ...

In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now. Following a turbulent year for the markets in general and biotech in particular, the industry made a notable ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Biotechnology stocks represent a great opportunity for investors who are fortunate enough to get into the right names at the right time. The biotech stock sector has always been a stellar performer in ...

Gaps are information. They are the place on the chart where you can see buyers and sellers jumping ahead to a fast repricing, usually in response to company-specific news that suddenly and ...

Jim Cramer called Nuvation Bio (NUVB) a “pure spec” on Mad Money as the biopharma stock surges on an FDA win. Here’s what it ...

Vir Biotechnology develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases such as COVID-19, hepatitis B, influenza A, and HIV. It generates revenue primarily through ...

Citi analyst Yigal Nochomovitz sees enormous upside in two biotech stocks, but those forecasts reveal as much about risk as potential reward. Nochomovitz has a $7 target on Biomea Fusion, implying ...

CRISPR Therapeutics is a gene editing specialist. It developed Casgevy, a medicine for two rare blood diseases, in collaboration with Vertex Pharmaceuticals. Casgevy doesn't generate much revenue yet, ...